Drug Profile
Research programme: SCAP ligands - GlaxoSmithKline
Alternative Names: GW 300; GW 532; GW 575; GW 707Latest Information Update: 19 Mar 2007
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class
- Mechanism of Action LDL receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 13 Feb 2002 New profile
- 13 Feb 2002 Preclinical development for Hyperlipidaemia in France (unspecified route)